Study of CMAB009 to Treat KRAS Wild Type Metastatic Colorectal Cancer

NCT01550055 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

512

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: CMAB009 plus Irinotecan
DRUG: Irinotecan-only and sequential-CMAB009

Sponsor

Shanghai Zhangjiang Biotechnology Limited Company

Collaborators

[object Object]